Antibody therapeutics targeting ion channels: Are we there yet?

Acta Pharmacologica Sinica

Volumn 34, Issue 2, 2013, Pages 199-204

  Sun, Han ^a   Li, Min ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibody; autoimmune neurological disorder; channelopathy; ion channel; protein based therapeutics

Indexed keywords

BETA SECRETASE 1; DIHYDROPYRIDINE; EPITOPE; ION CHANNEL; RECOMBINANT ANTIBODY; VOLTAGE GATED SODIUM CHANNEL;

ALZHEIMER DISEASE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CHANNELOPATHY; DEPOLARIZATION; DRUG TARGETING; FOLLOW UP; HUMAN; IC 50; IMMUNOSUPPRESSIVE TREATMENT; NEOPLASM; NEUROMUSCULAR SYNAPSE; NONHUMAN; PLASMAPHERESIS; PROTEIN TARGETING; REVIEW;

ANIMALS; ANTIBODIES; AUTOIMMUNE DISEASES; DRUG DISCOVERY; HUMANS; ION CHANNELS; MOLECULAR TARGETED THERAPY;

EID: 84873538403     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.202     Document Type: Review

References (44)

1. Vernino S. Autoimmune and paraneoplastic channelopathies. Neurotherapeutics 2007; 4: 305-14.
2. Vincent A, Lang B, Newsom-Davis J. Autoimmunity to the voltagegated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci 1989; 12: 496-502.
3. Pinto A, Gillard S, Moss F, Whyte K, Brust P, Williams M, et al. Human autoantibodies specific for the α1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci USA 1998; 95: 8328-33.
4. Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, et al. Acquired neuromyotonia: Evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 1995; 38: 714-22.
5. Tomimitsu H, Arimura K, Nagado T, Watanabe O, Otsuka R, Kurono A, et al. Mechanism of action of voltage-gated K+ channel antibodies in acquired neuromyotonia. Ann Neurol 2004; 56: 440-4.
6. Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain 2006; 129: 1570-84.
7. Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012; 367: 115-23.
8. Meiri H, Zeitoun I, Grunhagen HH, Lev-Ram V, Eshhar Z, Schlessinger J. Monoclonal antibodies associated with sodium channel block nerve impulse and stain nodes of ranvier. Brain Res 1984; 310: 168-73.
9. Moore HP, Fritz LC, Raftery MA, Brockes JP. Isolation and characterization of a monoclonal antibody against the saxitoxin-binding component from the electric organ of the eel Electrophorus electricus. Proc Natl Acad Sci USA 1982; 79: 1673-77.
10. Meiri H, Goren E, Bergmann H, Zeitoun I, Rosenthal Y, Palti Y. Specific modulation of sodium channels in mammalian nerve by monoclonal antibodies. Proc Natl Acad Sci USA 1986; 83: 8385-9.
11. Morikawa Y, Meiri H, Spinelli W, Rosen M, Robinson R. Modification of Vmax of canine cardiac Purkinje fibers and of the effects of lidocaine by SC-72-14. Circ Res 1985; 57: 354-61.
12. Barhanin J, Meiri H, Romey G, Pauron D, Lazdunski M. A monoclonal immunotoxin acting on the Na+ channel, with properties similar to those of a scorpion toxin. Proc Natl Acad Sci USA 1985; 82: 1842-6.
13. Morton ME, Froehner SC. Monoclonal antibody identifies a 200-kDa subunit of the dihydropyridine-sensitive calcium channel. J Biol Chem 1987; 262: 11904-7.
14. Morton ME, Caffrey JM, Brown AM, Froehner SC. Monoclonal antibody to the alpha 1-subunit of the dihydropyridine-binding complex inhibits calcium currents in BC3H1 myocytes. J Biol Chem 1988; 263: 613-6.
15. Wyatt CN, Campbell V, Brodbeck J, Brice NL, Page KM, Berrow NS, et al. Voltage-dependent binding and calcium channel current inhibition by an anti-alpha 1D subunit antibody in rat dorsal root ganglion neurones and guinea-pig myocytes. J Physio 1997; 502: 307-19.
16. Zhou BY, Ma W, Huang XY. Specific antibodies to the external vestibule of voltage-gated potassium channels block current. J Gen Physiol 1998; 111: 555-63.
17. Xu SZ, Zeng F, Lei M, Li J, Gao B, Xiong C, et al. Generation of functional ion-channel tools by E3 targeting. Nat Biotech 2005; 23: 1289-93.
18. Alkire MT, Asher CD, Franciscus AM, Hahn EL. Thalamic microinfusion of antibody to a voltage-gated potassium channel restores consciousness during anesthesia. Anesthesiology 2009; 110: 766-73.
19. Liao YJ, Safa P, Chen YR, Sobel RA, Boyden ES, Tsien RW. Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo. Proc Natl Acad Sci USA 2008; 105: 2705-10.
20. Rosado JA, Brownlow SL, Sage SO. Endogenously expressed Trp1 is involved in store-mediated Ca2+ entry by conformational coupling in human platelets. J Biol Chem 2002; 277: 42157-63.
21. Xu SZ, Beech DJ. TrpC1 is a Membrane-spanning subunit of storeoperated Ca2+ channels in native vascular smooth muscle cells. Circ Res 2001; 88: 84-7.
22. Antoniotti S, Lovisolo D, Fiorio Pla A, Munaron L. Expression and functional role of bTRPC1 channels in native endothelial cells. FEBS Lett 2002; 510: 189-95.
23. Ahmmed GU, Mehta D, Vogel S, Holinstat M, Paria BC, Tiruppathi C, et al. Protein kinase Cα phosphorylates the TRPC1 channel and regulates store-operated Ca2+ entry in endothelial cells. J Biol Chem 2004; 279: 20941-9.
24. Xu SZ, Boulay G, Flemming R, Beech DJ. E3-targeted anti-TRPC5 antibody inhibits store-operated calcium entry in freshly isolated pial arterioles. Am J Physiol Heart Circ Physiol 2006; 291: H2653-9.
25. Naylor J, Milligan CJ, Zeng F, Jones C, Beech DJ. Production of a specific extracellular inhibitor of TRPM3 channels. Br J Pharmacol 2008; 155: 567-73.
26. Tiwari-Woodruff S, Beltran-Parrazal L, Charles A, Keck T, Vu T, Bronstein J. K+ channel KV3.1 associates with OSP/claudin-11 and regulates oligodendrocyte development. Am J Physiol Cell Physiol 2006; 291: C687-98.
27. Gómez-Varela D, Zwick-Wallasch E, Knötgen H, Sánchez A, Hettmann T, Ossipov D, et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res 2007; 67: 7343-9.
28. Agarwal J, Griesinger F, Stuhmer W, Pardo L. The potassium channel Ether a go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer 2010; 9: 18.
29. Schwartz A, Palti Y, Meiri H. Structural and developmental differences between three types of Na channels in dorsal root ganglion cells of newborn rats. J Membr Biol 1990; 116: 117-28.
30. Sammar M, Spira G, Meiri H. Depolarization exposes the voltage sensor of the sodium channels to the extracellular region. J Membr Biol 1992; 125: 1-11.
31. Chioni AM, Fraser SP, Pani F, Foran P, Wilkin GP, Diss JKJ, et al. A novel polyclonal antibody specific for the Nav1.5 voltage-gated Na+ channel 'neonatal' splice form. J Neurosci Methods 2005; 147: 88-98.
32. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-16.
33. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12: 278-87.
34. Moskal JR, Kuo AG, Weiss C, Wood PL, O'Connor Hanson A, Kelso S, et al. GLYX-13: A monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology 2005; 49: 1077-87.
35. Zhang XL, Sullivan JA, Moskal JR, Stanton PK. A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 2008; 55: 1238-50.
36. Burgdorf J, Zhang XL, Weiss C, Matthews E, Disterhoft JF, Stanton PK, et al. The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging 2011; 32: 698-706.
37. Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 2012; 503: 269-92.
38. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 2011; 3: 84ra43.
39. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011; 3: 84ra44.
40. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6: 343-57.
41. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10: 345-52.
42. Meiri H. Detection of cell surface sodium channels by monoclonal antibodies-could the channels become exposed to the external surface and 'down regulated' by binding to antibodies? Brain Res 1986; 368: 188-92.
43. Barry E, Viglione M, Kim Y, Froehner S. Expression and antibody inhibition of P-type calcium channels in human small-cell lung carcinoma cells. J Neurosci 1995; 15: 274-83.
44. Klionsky L, Tamir R, Holzinger B, Bi X, Talvenheimo J, Kim H, et al. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation. J Pharmacol Exp Ther 2006; 319: 192-8.